| abstract |
The present invention provides a method and a composition for cellular immunotherapy. Specifically, the present invention provides a method for treating diseases associated with CD7 expression, comprising administering to a subject a first dose of engineered immune cells containing a chimeric antigen receptor that specifically binds to CD7, the first dose being 0.1x10 6 to 1x10 8 CAR+ cells/kg, wherein the subject receives a lymphodepletion therapy, prior to administration of the first dose, the lymphodepletion therapy comprising cyclophosphamide, fludarabine, etoposide, melphalan, or a combination thereof. |